91 results about "Guanylate cyclase" patented technology

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and / or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, a PDE-5 inhibitor, a compound that elevates cGMP and / or PKG, a stimulator of guanylyl cyclase and / or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity.

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

This invention provides a new therapeutic or prophylactic agent for arthritis such as osteoarthritis. Specifically, it provides a therapeutic or prophylactic agent for arthritis such as osteoarthritis, or an agent for promoting the growth of articular chondrocyte, comprising a guanyl cyclase B (GC-B) activator as an active ingredient; or a method for inhibiting arthritis or for promoting the growth of articular chondrocyte by activating GC-B; or a method for screening an agent for promoting the growth of articular chondrocyte or an agent capable of treating arthritis using the GC-B activity as an indication.

Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.

This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and / or sexual dysfunction.

This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

[Problem] To provide an excellent therapeutic or prophylactic agent for cardiovascular diseases on the basis of cGMP production-increasing activity attributed to soluble guanylate cyclase-activating activity. [Solution] It was discovered that an imidazopyridine compound having a carbamoyl group at the 3-position of an imidazo[1,2-a]pyridine skeleton and having a substituent attached to the 8-position of the skeleton through an oxygen atom exhibits cGMP production-increasing activity attributed to potent soluble guanylate cyclase-activating activity and can be used in an excellent therapeutic or prophylactic agent for various cardiovascular diseases associated with soluble guanylate cyclase, and the invention was completed.

This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

We disclose a method of inhibiting activity of adenylyl cyclase or guanylyl cyclase in a mammal by administering to the mammal an amount of a composition effective to inhibit the activity, wherein the composition contains at least one compound selected from the group consisting of structural formulae (Ia) and (Ib) and salts thereof, wherein R1 is —H or has the structure —C(═O)R8; R2 is ═O or has the structure —OC(═O)R9; and R3, R4, R5, R6, and R7 are each independently selected from the group consisting of —H, —NO2, formula (I), -halogen, —OC(═O)R9, —OR9, —OH, —R8OH, —CH3, —OC(═O)CH2Ph, formulae (II), (III), (IV), —OPh, —CF3, —R8, —C(═O)OR9, -Ph, —R8Ph, formulae (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), and (XXI), wherein each R8 is independently a linear or branched hydrocarbon group having from 1 to 4 carbon atoms and each R9 is independently a hydrocarbon group having from 1 to 2 carbon atoms. Administering the composition can be used to treat a disease in a mammal mediated by activity of adenylyl cyclase or guanylyl cyclase and effected by a toxin produced by a pathogenic organism or to reduce cyclic AMP or cyclic GMP levels in a mammal in need of reduction thereof. The composition can also be administered to mammalian cells in vitro. The above methods of inhibiting activity of adenylyl cyclase or guanylyl cyclase and treating diseases via such inhibition can be effective without prolonged treatment, have reversible effects, have low or no toxicity, are highly potent, are unlikely to have side effects, do not act on purinergic receptors, or can negate pathogenic toxins independently of whether the pathogenic organism survives.

The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys GIu Tyr Cys Cys Asn Pro Ala Cys Thr GIy Cys Tyr ("linaclotide") or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Disclosed are methods of selectively delivering a medicant to an abnormal brain region and / or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel agonist (other than bradykinin or a bradykinin analog), such as NS-1619,1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim, whereby the medicant is delivered selectively to the cells of the abnormal brain region and / or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel agonist together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and / or to a malignant tumor.

This invention provides a method to prevent, control, and / or treat an inflammatory disease or disorder by administering at least one agonist of guanalyte cyclase receptor, or pharmaceutical compositions thereof, either alone or either concurrently or sequentially with another compound or an active agent used to treat the disease or disorder, and / or with an inhibitor of cGMP-dependent phosphodieasterases.

The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment of Cystic Fibrosis (CF).

A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and / or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.

The invention relates to a natural activator of soluble guanylate cyclase, which is characterized in that the soluble guanylate cyclase in a human circulatory system is used as a selected target; <3>Hisotope is used for marking; and natural components capable of activating the soluble guanylate cyclase are selected from plant medicaments for treating cardiovascular-related diseases in Chinese, Indian and European traditional medicine. The natural components capable of activating the soluble guanylate cyclase in the human circulatory system under the condition of vitro experiments are obtainedthrough screening, and structure searches and further activation analyses are carried out on the natural components and metabolic components thereof in the human body. The mother nucleus structure ofa substance capable of activating the soluble guanylate cyclase and the side chain structure information of the mother nucleus are obtained so as to provide the pertinent information for the researchand development of medicaments related to the treatment of cardiovascular diseases relating to the soluble guanylate cyclase-cGMP signal conduction path.

The invention relates to the expression of the cDNA clone for sub-units a1 (hsGCa1) and b1 (hsGCb1) of human soluble guanylylcyclase and the subsequent purification of the active enzyme and use thereof, the medical application of the expression of this clone by gene transfer, in addition to antibodies against peptides derived from said sequence and the use thereof.

The invention provides a diguanylate cyclase gene for coding diguanylate cyclase, a recombinant vector containing the gene, recombinant gene engineering bacteria obtained by transformation of the recombinant vector, and application thereof in the preparation of recombinant diguanylate cyclase. The diguanylate cyclase can be bonded with an expression vector to construct intracellular expression recombinant plasmid containing the genes for respectively correspondingly transforming to escherichia coli to obtain recombinant escherichia coli. The recombinant escherichia coli containing the recombinant diguanylate cyclase can be used as an enzyme source for biological catalysis and transformation. The recombinant diguanylate cyclase as a transformation enzyme can use 5'-guanosine triphosphate (GTP) trisodium as a substrate for transformation for preparation of cyclic di-guanylic monophosphate (c-di-GMP).

The invention discloses the combined application of a pharmaceutical composition composed of water-soluble starch salt modified by carboxylic acid groups and gastrointestinal motility promoting drugsor secretion promoting drugs in the prevention and treatment of constipation, the pharmaceutical composition can be suitable for various functional constipation, especially has good curative effects on old age refractory constipation, chronic constipation, habitual constipation, drug-induced constipation and the like, has slight adverse reactions, and can be suitable for various crowds. The representative drug of the water-soluble starch salt modified by the carboxylic acid groups is sodium carboxymethyl starch, and the gastrointestinal motility promoting drugs or secretion promoting drugs areselected from dopamine receptor antagonist, 5-HT4 receptor agonist, motilin receptor agonist, chloridion channel activator, guanylate cyclase agonist. The two components are combined according to a suitable weight ratio and can be prepared into any oral pharmaceutical dosage form including oral solution, oral suspension, granule, powder, tablet, capsule and the like.

The present invention relates to novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes.

Disclosed are methods of selectively delivering a medicant to an abnormal brain region and / or to a malignant tumor In a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel agonist (other than bradykinin or a bradykinin analog), such as NS-1619,1-EBIO, a guanylyl cyclase activator, a guanylyl cyclase activating protein, minoxidil, pinacidil, cromakalim, or levcromakalim, whereby the medicant is delivered selectively to the cells of the abnormal brain region and / or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel agonist together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and / or to a malignant tumor.

A composition containing cAMP, cGMP, forskolin, adenylate cyclase or guanylate cyclase and microorganisms is provided to facilitate bioremediation, detoxication and to enhance plant growth in media contaminated with petroleum hydrocarbons. Methods to make the composition and apply it to the contaminated media in order to facilitate bioremediation and detoxication of such contaminants are also provided.